AstraZeneca PLC Form 6-K Filing Summary

This Form 6-K report details AstraZeneca PLC's announcement regarding Enhertu's recommendation for approval in the EU. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended Enhertu for adjuvant treatment of HER2-positive early breast cancer patients with residual disease after neoadjuvant treatment. This recommendation is based on the DESTINY-Breast05 Phase III trial, which demonstrated that Enhertu reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1. If approved, Enhertu could become a new standard of care in this setting, potentially redefining post-surgery care and improving long-term outcomes for patients. The report also provides comprehensive background information on HER2-positive breast cancer, the DESTINY-Breast05 trial, and Enhertu's development and regulatory status across various indications and regions. AstraZeneca and Daiichi Sankyo are jointly developing and commercializing Enhertu.